UNSPSC 51384516: Pranoprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2R7O1ET613, chemically known as 5h-(1)benzopyrano(2,3,-b)pyridine-7-acetic acid, alpha-methyl- but generally known as pranoprofen, which bears US NIH Compound Identifier 4888. European Medicines Agency schedules Pranoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10000MIG.

UNSPSC 51384516 Pranoprofen (Commodity) shows a disconnect between its nominal scope and actual state and local procurement activity captured in recent opportunities. The code is tagged to pharmaceutical and health-related procurement, yet recent solicitations posted under it involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which are pranoprofen-specific acquisitions. The issuing bodies span state health agencies, county health departments, and multistate cooperative purchasing alliances: Seminole County, Florida (community health); Texas Health and Human Services Commission (pharmacy benefit program); and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which serves participating state and local government facilities across multiple states including Oregon. The actual work being solicited is the procurement and distribution of pharmaceuticals, OTC products, and related health-intervention systems through competitive and cooperative contracting mechanisms, not the purchase of pranoprofen as a distinct commodity.

The geographic footprint reflects activity in Florida, Texas, and the Upper Midwest through MMCAP's multistate membership. Recent opportunities include Seminole County's IFB IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products with award effective July 1, 2026. The code shows limited or misaligned recent activity; no solicitations are explicitly requesting pranoprofen procurement.